vs

Side-by-side financial comparison of EnerSys (ENS) and Moderna (MRNA). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $919.1M, roughly 1.1× EnerSys). EnerSys runs the higher net margin — 9.8% vs -19.7%, a 29.5% gap on every dollar of revenue. On growth, EnerSys posted the faster year-over-year revenue change (1.4% vs -45.4%). EnerSys produced more free cash flow last quarter ($171.3M vs $-880.0M). Over the past eight quarters, EnerSys's revenue compounded faster (0.5% CAGR vs -45.0%).

EnerSys is a stored energy systems and technology provider for industrial applications. The company manufactures reserve-power and motive-power batteries, battery chargers, power equipment, battery accessories and outdoor equipment enclosures.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

ENS vs MRNA — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.1× larger
MRNA
$1.0B
$919.1M
ENS
Growing faster (revenue YoY)
ENS
ENS
+46.9% gap
ENS
1.4%
-45.4%
MRNA
Higher net margin
ENS
ENS
29.5% more per $
ENS
9.8%
-19.7%
MRNA
More free cash flow
ENS
ENS
$1.1B more FCF
ENS
$171.3M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
ENS
ENS
Annualised
ENS
0.5%
-45.0%
MRNA

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
ENS
ENS
MRNA
MRNA
Revenue
$919.1M
$1.0B
Net Profit
$90.4M
$-200.0M
Gross Margin
30.1%
79.6%
Operating Margin
13.5%
-25.6%
Net Margin
9.8%
-19.7%
Revenue YoY
1.4%
-45.4%
Net Profit YoY
-21.3%
-1638.5%
EPS (diluted)
$2.40
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENS
ENS
MRNA
MRNA
Q4 25
$919.1M
Q3 25
$951.3M
$1.0B
Q2 25
$893.0M
Q1 25
$974.8M
Q4 24
$906.2M
$966.0M
Q3 24
$883.7M
$1.9B
Q2 24
$852.9M
Q1 24
$910.7M
Net Profit
ENS
ENS
MRNA
MRNA
Q4 25
$90.4M
Q3 25
$68.4M
$-200.0M
Q2 25
$57.5M
Q1 25
$96.5M
Q4 24
$114.8M
$-1.1B
Q3 24
$82.3M
$13.0M
Q2 24
$70.1M
Q1 24
$60.9M
Gross Margin
ENS
ENS
MRNA
MRNA
Q4 25
30.1%
Q3 25
29.1%
79.6%
Q2 25
28.4%
Q1 25
31.2%
Q4 24
32.9%
23.5%
Q3 24
28.5%
72.4%
Q2 24
27.9%
Q1 24
27.9%
Operating Margin
ENS
ENS
MRNA
MRNA
Q4 25
13.5%
Q3 25
9.7%
-25.6%
Q2 25
9.7%
Q1 25
13.5%
Q4 24
15.7%
-129.0%
Q3 24
11.2%
-3.8%
Q2 24
10.7%
Q1 24
8.9%
Net Margin
ENS
ENS
MRNA
MRNA
Q4 25
9.8%
Q3 25
7.2%
-19.7%
Q2 25
6.4%
Q1 25
9.9%
Q4 24
12.7%
-115.9%
Q3 24
9.3%
0.7%
Q2 24
8.2%
Q1 24
6.7%
EPS (diluted)
ENS
ENS
MRNA
MRNA
Q4 25
$2.40
Q3 25
$1.80
$-0.51
Q2 25
$1.46
Q1 25
$2.39
Q4 24
$2.88
$-2.91
Q3 24
$2.01
$0.03
Q2 24
$1.71
Q1 24
$1.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENS
ENS
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$450.1M
$1.1B
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$9.3B
Total Assets
$4.0B
$12.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENS
ENS
MRNA
MRNA
Q4 25
$450.1M
Q3 25
$388.6M
$1.1B
Q2 25
$346.7M
Q1 25
$343.1M
Q4 24
$463.2M
$1.9B
Q3 24
$407.9M
$1.6B
Q2 24
$344.1M
Q1 24
$333.3M
Total Debt
ENS
ENS
MRNA
MRNA
Q4 25
Q3 25
Q2 25
Q1 25
$1.1B
Q4 24
Q3 24
Q2 24
Q1 24
$802.0M
Stockholders' Equity
ENS
ENS
MRNA
MRNA
Q4 25
$1.9B
Q3 25
$1.9B
$9.3B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$1.8B
$10.9B
Q3 24
$1.8B
$11.9B
Q2 24
$1.8B
Q1 24
$1.8B
Total Assets
ENS
ENS
MRNA
MRNA
Q4 25
$4.0B
Q3 25
$4.1B
$12.1B
Q2 25
$4.1B
Q1 25
$4.0B
Q4 24
$4.0B
$14.1B
Q3 24
$4.0B
$15.8B
Q2 24
$3.6B
Q1 24
$3.5B
Debt / Equity
ENS
ENS
MRNA
MRNA
Q4 25
Q3 25
Q2 25
Q1 25
0.57×
Q4 24
Q3 24
Q2 24
Q1 24
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENS
ENS
MRNA
MRNA
Operating Cash FlowLast quarter
$184.6M
$-847.0M
Free Cash FlowOCF − Capex
$171.3M
$-880.0M
FCF MarginFCF / Revenue
18.6%
-86.6%
Capex IntensityCapex / Revenue
1.4%
3.2%
Cash ConversionOCF / Net Profit
2.04×
TTM Free Cash FlowTrailing 4 quarters
$441.3M
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENS
ENS
MRNA
MRNA
Q4 25
$184.6M
Q3 25
$218.0M
$-847.0M
Q2 25
$968.0K
Q1 25
$135.2M
Q4 24
$81.1M
$825.0M
Q3 24
$33.6M
$-1.6B
Q2 24
$10.4M
Q1 24
Free Cash Flow
ENS
ENS
MRNA
MRNA
Q4 25
$171.3M
Q3 25
$197.1M
$-880.0M
Q2 25
$-32.1M
Q1 25
$104.9M
Q4 24
$56.8M
$303.0M
Q3 24
$3.3M
$-1.7B
Q2 24
$-25.7M
Q1 24
FCF Margin
ENS
ENS
MRNA
MRNA
Q4 25
18.6%
Q3 25
20.7%
-86.6%
Q2 25
-3.6%
Q1 25
10.8%
Q4 24
6.3%
31.4%
Q3 24
0.4%
-92.2%
Q2 24
-3.0%
Q1 24
Capex Intensity
ENS
ENS
MRNA
MRNA
Q4 25
1.4%
Q3 25
2.2%
3.2%
Q2 25
3.7%
Q1 25
3.1%
Q4 24
2.7%
54.0%
Q3 24
3.4%
8.1%
Q2 24
4.2%
Q1 24
Cash Conversion
ENS
ENS
MRNA
MRNA
Q4 25
2.04×
Q3 25
3.19×
Q2 25
0.02×
Q1 25
1.40×
Q4 24
0.71×
Q3 24
0.41×
-120.46×
Q2 24
0.15×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENS
ENS

Energy Systems$399.5M43%
Motive Power$352.0M38%
Services$92.6M10%
Transferred Over Time$38.2M4%
Other$36.8M4%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons